Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/dose-dependent-growth-inhibition-in-vivo-of-pc-3-prostate-cancer-with-9ODcwZl7K0
References (40)
-
J Pinski, AV Schally, G Halmos, K Szepeshazi (1993)
Effect of somatostatin analog RC‐160 and bombesin/gastrin releasing peptide antagonist RC‐3095 on growth of PC‐3 human prostate‐cancer xenografts in nude mice, 55
-
A Stangelberger, AV Schally, M Zarandi, E Heinrich, K Groot, A Havt, CA Kanashiro, JL Varga, G Halmos (2007)
The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA‐PCa‐2b and LuCaP‐35 prostate cancers, 67
-
A Jungwirth, AV Schally, J Pinski, G Halmos, K Groot, P Armatis, M Vadillo‐Buenfil (1997)
Inhibition of in vivo proliferation of androgen‐independent prostate cancers by an antagonist of growth hormone‐releasing hormone, 75
-
D González‐Barcena, AV Schally, M Vadillo‐Buenfil, A Cortez‐Morales, LV Hernández, I Cardenas‐Cornejo, AM Comaru‐Schally (2003)
Response of patients with advanced prostatic cancer to administration of somatostatin analog RC‐160 (vapreotide) at the time of relapse, 56
-
AV Schally, AM Comaru‐Schally (2006)
Cancer medicine -
M Mimeault, N Pommery, JP Henichart (2003)
New advances on prostate carcinogenesis and therapies: Involvement of EGF‐EGFR transduction system, 21
-
G Halmos, AV Schally, T Czompoly, M Krupa, JL Varga, Z Rekasi (2002)
Expression of growth hormone‐releasing hormone and its receptor splice variants in human prostate cancer, 87
-
M Letsch, AV Schally, R Busto, AM Bajo, JL Varga (2003)
Growth hormone‐releasing hormone (GHRH) antagonists inhibit the proliferation of androgen‐dependent and ‐independent prostate cancers, 100
-
A Stangelberger, AV Schally, JL Varga, M Zarandi, K Szepeshazi, P Armatis, G Halmos (2005)
Inhibitory effect of antagonists of bombesin and growth hormone‐releasing hormone on orthotopic and intraosseous growth and invasiveness of PC‐3 human prostate cancer in nude mice, 11
-
G Keller, AV Schally, K Groot, GL Toller, A Havt, F Koster, P Armatis, G Halmos, M Zarandi, JL Varga, JB Engel (2005)
Effective treatment of experimental human non‐Hodgkin's lymphomas with antagonists of growth hormone‐releasing hormone, 102
-
JB Engel, AV Schally (2007)
Drug Insight: Clinical use of agonists and antagonists of luteinizing‐hormone‐releasing hormone, 3
-
Schally (2000)
Peptide analogs in the therapy of prostate cancerProstate, 45
-
AV Schally, AM Comaru‐Schally, A Nagy, M Kovacs, K Szepeshazi, A Plonowski, JL Varga, G Halmos (2001)
Hypothalamic hormones and cancer, 22
-
BH Breier, BW Gallaher, PD Gluckman (1991)
Radioimmunoassay for insulin‐like growth factor‐I: Solutions to some potential problems and pitfalls, 128
-
M Zarandi, JL Varga, AV Schally, JE Horvath, GL Toller, M Kovacs, M Letsch, K Groot, P Armatis, G Halmos (2006)
Lipopeptide antagonists of growth hormone‐releasing hormone with improved antitumor activities, 103
-
D Gonzalez‐Barcena, M Vadillo‐Buenfil, F Gomez‐Orta, M Fuentes Garcia, I Cardenas‐Cornejo, A Graef‐Sanchez, AM Comaru‐Schally, AV Schally (1994)
Responses to the antagonistic analog of LH‐RH (SB‐75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer, 24
-
A Plonowski, AV Schally, JL Varga, Z Rekasi, F Hebert, G Halmos, K Groot (2000)
Potentiation of the inhibitory effect of growth hormone‐releasing hormone antagonists on PC‐3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways, 44
-
N Lamharzi, AV Schally, M Koppan, K Groot (1998)
Growth hormone‐releasing hormone antagonist MZ‐5‐156 inhibits growth of DU‐145 human androgen‐independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin‐like growth factor II in tumors, 95
-
H Kiaris, AV Schally, R Busto, G Halmos, S Artavanis‐Tsakonas, JL Varga (2002)
Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs, 99
-
D Gonzalez‐Barcena, M Vadillo‐Buenfil, A Cortez‐Morales, M Fuentes‐Garcia, I Cardenas‐Cornejo, AM Comaru‐Schally, AV Schally (1995)
Luteinizing hormone‐releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord, 45
-
Feldman (2001)
The development of androgen-independent prostate cancerNat Rev Cancer, 1
-
Tannock (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerN Engl J Med, 351
-
Z Culig, A Hobisch, MV Cronauer, AC Cato, A Hittmair, C Radmayr, J Eberle, G Bartsch, H Klocker (1993)
Mutant androgen receptor detected in an advanced‐stage prostatic carcinoma is activated by adrenal androgens and progesterone, 7
-
M Letsch, AV Schally, A Stangelberger, K Groot, JL Varga (2004)
Antagonists of growth hormone‐releasing hormone (GH‐RH) enhance tumour growth inhibition induced by androgen deprivation in human MDA‐Pca‐2b prostate cancers, 40
-
A Stangelberger, AV Schally, JL Varga, BD Hammann, K Groot, G Halmos, RZ Cai, M Zarandi (2005)
Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC‐3 and DU‐145 human androgen‐independent prostate cancers, 64
-
Z Culig, A Hobisch, MV Cronauer, C Radmayr, J Trapman, A Hittmair, G Bartsch, H Klocker (1994)
Androgen receptor activation in prostatic tumor cell lines by insulin‐like growth factor‐I, keratinocyte growth factor, and epidermal growth factor, 54
-
AV Schally, JL Varga, JB Engel (2008)
Antagonists of growth hormone‐releasing hormone: An emerging new therapy for cancer, 4
-
A Havt, AV Schally, G Halmos, JL Varga, GL Toller, JE Horvath, K Szepeshazi, F Koster, K Kovitz, K Groot, M Zarandi, CA Kanashiro (2005)
The expression of the pituitary growth hormone‐releasing hormone receptor and its splice variants in normal and neoplastic human tissues, 102
-
GO Hellawell, GD Turner, DR Davies, R Poulsom, SF Brewster, VM Macaulay (2002)
Expression of the type 1 insulin‐like growth factor receptor is up‐regulated in primary prostate cancer and commonly persists in metastatic disease, 62
-
AV Schally, JL Varga (1999)
Antagonistic analogs of growth hormone‐releasing hormone: New potential antitumor agents, 10
-
LK Chopin, AC Herington (2001)
A potential autocrine pathway for growth hormone releasing hormone (GHRH) and its receptor in human prostate cancer cell lines, 49
-
J Pinski, G Halmos, AV Schally (1993)
Somatostatin analog RC‐160 and bombesin/gastrin‐releasing peptide antagonist RC‐3095 inhibit the growth of androgen‐independent DU‐145 human prostate cancer line in nude mice, 71
-
D Djakiew (2000)
Dysregulated expression of growth factors and their receptors in the development of prostate cancer, 42
-
Z Rekasi, T Czompoly, AV Schally, G Halmos (2000)
Isolation and sequencing of cDNAs for splice variants of growth hormone‐releasing hormone receptors from human cancers, 97
-
A Plonowski, AV Schally, R Busto, M Krupa, JL Varga, G Halmos (2002)
Expression of growth hormone‐releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers, 23
-
Loblaw (2004)
American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancerJ Clin Oncol, 22
-
AV Schally, JL Varga (2006)
Antagonists of growth hormone‐releasing hormone in oncology, 9
-
LK Kvols, EA Woltering (2006)
Role of somatostatin analogs in the clinical management of non‐neuroendocrine solid tumors, 17
-
NM Hoosein, CJ Logothetis, LW Chung (1993)
Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC‐160 on the invasive capacity of human prostatic carcinoma cells, 149
-
A Plonowski, AV Schally, M Letsch, M Krupa, F Hebert, R Busto, K Groot, JL Varga (2002)
Inhibition of proliferation of PC‐3 human prostate cancer by antagonists of growth hormone‐releasing hormone: Lack of correlation with the levels of serum IGF‐I and expression of tumoral IGF‐II and vascular endothelial growth factor, 52
- Publisher
- Wiley
- Copyright
- Copyright © 2008 Wiley Subscription Services
- ISSN
- 0270-4137
- eISSN
- 1097-0045
- DOI
- 10.1002/pros.20843
- pmid
- 18729085
- Publisher site
- See Article on Publisher Site
Abstract
Journal
The Prostate – Wiley
Published: Jan 1, 2008
Keywords: ; ; ;